Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Therapie ; 66(1): 25-8, 2011.
Article in French | MEDLINE | ID: mdl-21466774

ABSTRACT

Following the announcement of the future withdrawal in Europe of drugs containing dextropropoxyphene-paracetamol (DXP-P), we performed a postal survey in a randomly selected sample of 350 general practitioners (GP) from the Midi-Pyrénées area (2.6 million inhabitants) in order to investigate which drug (s) they are willing to prescribe in anticipation of the announced withdrawal. Most of GP prescribed DXP-P in acute and chronic pain. In acute pain, GP would switch to codeine-paracetamol (59.1%) or tramadol alone or associated with paracetamol (79%), whereas they would switch to high dose paracetamol (54.7%) and tramadol alone or associated with paracetamol (74.6%) in chronic pain. Switching to other level 2 analgesic drugs after the withdrawal of dextropropoxyphene should be closely monitored because the safety profile of other drugs.


Subject(s)
Acetaminophen/adverse effects , Analgesics, Non-Narcotic/adverse effects , Analgesics, Opioid/adverse effects , Dextropropoxyphene/adverse effects , Pain Management/trends , Product Recalls and Withdrawals , Acute Pain/drug therapy , Chronic Pain/drug therapy , Codeine/therapeutic use , Drug Combinations , Drug Utilization , Health Care Surveys , Humans , Surveys and Questionnaires , Tramadol/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...